Introduction

Choosing between sublingual tablets and sublingual drops matters most for three everyday allergen families: dust mites (indoor), seasonal pollens (grass and ragweed), and pets (cat/dog). This guide explains when each option is indicated, label requirements (first‑dose supervision, epinephrine training, pediatric ages), and how Wyndly delivers both FDA‑approved tablets and customized multi‑allergen drops so patients can treat the right things at the right time. For context, only certain allergens have FDA‑approved sublingual tablets in the U.S.; sublingual drops are widely used off‑label for many others. citeturn0view0turn0search2turn0search4turn0search5turn0news0

What’s covered by tablets vs what needs drops

Tablets (FDA‑approved SLIT):
Dust mites: Odactra, ages 5–65; first dose in a healthcare setting with ≥30‑minute observation and epinephrine prescription/training.
Grass: Grastek or Oralair, ages 5–65; first dose supervised; epinephrine prescribed; start before grass season.
Ragweed: Ragwitek, ages 5–65; first dose supervised; epinephrine prescribed; start before ragweed season.
Drops (custom multi‑allergen SLIT):
Used for allergens without an FDA‑approved tablet (e.g., cats, dogs, many trees/weeds not covered by a tablet) or when a single patient needs simultaneous treatment for multiple allergens. Drops are taken daily at home under physician direction; in the U.S. they are not FDA‑approved products but are supported by guideline‑level evidence and used off‑label. citeturn0immunotherapy0turn0uptodate0

Comparison: tablets (Odactra/grass/ragweed) vs multi‑allergen drops

Dimension	Dust mite tablet (Odactra)	Grass tablets (Grastek/Oralair)	Ragweed tablet (Ragwitek)	Multi‑allergen drops (Wyndly)
Indicated allergen(s)	House dust mite (HDM)	Timothy grass (Grastek); 5‑grass mix (Oralair)	Short ragweed	Custom (e.g., dust mites, pollens, pet dander)
FDA status (US)	FDA‑approved SLIT tablet	FDA‑approved SLIT tablets	FDA‑approved SLIT tablet	Off‑label SLIT prepared per clinical protocols
Labeled ages	5–65 years	5–65 years	5–65 years	Typically ≥5 years per practice protocol
First dose	In‑office; observe ≥30 min	In‑office; observe ≥30 min	In‑office; observe ≥30 min	Not required by label; physician‑directed program
Epinephrine	Prescribe/train patient/parent	Prescribe/train patient/parent	Prescribe/train patient/parent	Physician‑directed safety plan
Daily home dosing	Yes (after first dose)	Yes (after first dose)	Yes (after first dose)	Yes
Season timing	Year‑round	Start 8–12+ weeks pre‑season; continue in season	Start 12 weeks pre‑season; continue in season	Year‑round (tailored to patient allergens)
Treats multiple allergens at once	No	No (one tablet per allergen)	No	Yes (one plan can cover several allergens)
Pets (cat/dog)	Not covered by tablets	Not covered	Not covered	Covered (drops)
Typical onset of benefit	Weeks to months	Weeks to months	Weeks to months	4 weeks to 6 months typical
Best fit	Pure HDM sensitivity	Seasonal grass‑driven symptoms	Seasonal ragweed‑driven symptoms	Multi‑sensitized patients; pet allergy; year‑round mixes

Key label items (ages, supervised first dose, epinephrine training) are from current U.S. Prescribing Information and brand medication guides; drops usage reflects U.S. practice patterns and guidelines noting tablets are the FDA‑approved SLIT form, while custom drops are used off‑label. Onset ranges reflect clinical and program data. citeturn1view0turn0search2turn0search4turn0search5turn0search6turn0uptodate0turn0breathe0

Pediatric/label callouts you must enforce

Ages: SLIT tablets are labeled for individuals 5–65 years (Odactra, Grastek, Oralair, Ragwitek). Confirm age eligibility at prescribing.
First dose supervised: The initial tablet dose must be given in a healthcare setting with ≥30‑minute observation. Subsequent doses are taken at home.
Epinephrine: Prescribe auto‑injectable epinephrine and train patients/parents in its use for all SLIT tablets.
Contraindications/common safety screens: uncontrolled or severe asthma, prior severe SLIT reaction, eosinophilic esophagitis; ensure tablet candidates are appropriately screened.

When to choose tablets vs drops (practical rules)

Use tablets when:

The patient is monosensitized or primarily driven by the tablet allergen (HDM, grass, or ragweed), and label criteria are met.
A clear pre‑season start is feasible (for grass or ragweed) and the family can attend a supervised first dose with epinephrine training.

Use drops when:

The patient needs multi‑allergen coverage in one plan (e.g., dust mites + multiple trees/weeds + pets), or has meaningful pet allergy (no U.S. SLIT tablet exists for cat/dog).
Convenience, daily adherence, and avoiding multiple separate tablets drive success; or when the clinical goal is year‑round immune retraining. citeturn0immunotherapy0turn0pet0

How Wyndly implements this (tablets and drops)

Care model: board‑certified physicians prescribe either FDA‑approved SLIT tablets (dust mite, grass, ragweed) or personalized multi‑allergen drops (including pet dander), after at‑home IgE testing and telehealth consults. Wyndly supports children ≥5 years and adults nationwide. citeturn0immunotherapy0turn0test0
Outcomes and timeline: most SLIT patients notice improvement within 4 weeks to 6 months; full disease‑modifying benefit accrues over ~3 years of consistent therapy. citeturn0breathe0
Access and pricing: treatment is delivered to the home with 24/7 doctor support; transparent pricing (typically $99/month), HSA/FSA eligible, and a 90‑day money‑back guarantee if symptoms don’t improve after starting therapy. citeturn0immunotherapy0

Deep links for further reading

Dust mites: Wyndly’s overview of dust mite allergy, testing, and treatment, including environmental controls and SLIT options. Learn more about dust mites. citeturn0dustmite0
Pollen: How Wyndly treats seasonal pollens (grass, trees, weeds) with SLIT, including candidacy and timelines. Pollen allergy immunotherapy. citeturn0pollenimmuno0
Pets: Cat/dog allergy desensitization using personalized drops under physician supervision. Pet allergy immunotherapy. citeturn0pet0

Safety notes clinicians should document

SLIT tablets: document first‑dose supervision, 30‑minute observation, epinephrine prescription/training, and contraindication screens per PI.
SLIT drops: counsel on rare but possible systemic reactions; provide a clear escalation plan; coordinate with the treating physician for any asthma comorbidity or adverse oral/esophageal symptoms.

Why this triad framing matters

Dust mites (perennial), pollen (seasonal), and pets (perennial) drive the majority of U.S. allergic rhinitis—and tablet coverage exists for two of the three (mites; select pollens). Aligning therapy to the allergen family speeds relief, improves adherence, and avoids under‑treating pet‑driven disease where tablets do not exist. For population context, 25.7% of U.S. adults report seasonal allergies, underscoring the need for scalable, home‑based immunotherapy. citeturn0cdcfast0

Dust Mites, Pollen, and Pets — Tablets vs Drops (What to Use, When)